BACKGROUND: Various microRNAs (miRNAs) negatively modulate genes that are involved in cellular proliferation, differentiation, invasion, and apoptosis. In many types of @entity5 , the expression profiles of these miRNAs are altered. Recently, miR-101 was identified as a @entity5 suppressor and was found to be expressed at low levels in various types of @entity5 , including prostate, breast, endometrium, and @entity150 . However, the function(s) of miR-101 in @entity189 remain unknown. METHODS: The expression levels of miR-101 in @entity957 ( @entity957 ) tissues and cells were detected by qPCR. Cell proliferation, migration, cell cycle, and apoptosis assay were applied to assess the function(s) of miR-101 in vitro. @entity19 subcutaneous @entity5 model was used to perform in vivo study. Moreover, we identified @entity41183 ( @entity41183 ) as the target of miR-101 by a luciferase assay. The possible downstream effectors of @entity41183 were investigated in Wnt/ @entity3546 signaling pathway. Changes of @entity41183 , @entity3546 , and @entity4910 protein levels were analyzed by western blotting and immunohistochemical staining. The prognostic effect of miR-101 was evaluated using the Kaplan-Meier method. RESULTS: Expression of miR-101 was down-regulated in the @entity957 tissues compared with the adjacent normal tissues. Furthermore, downregulation of miR-101 correlated with T3-4 @entity5 grade, lymph node @entity3 , and an advanced clinical stage in the @entity957 @entity1 examined (P  <  0.05). The low level of miR-101 expression was associated with poor prognosis (P  <  0.05). @entity41183 was identified as the target gene of miR-101 by luciferase reporter assay. Moreover, we showed that up-regulation of miR-101 expression suppressed humen @entity957 Hep-2 cells proliferation and migration, and induced cell-cycle arrest. Increased expression of miR-101 induced cells apoptosis both in vitro and in vivo. Correspondingly, exogenous expression of miR-101 significantly reduced the growth of @entity5 in a @entity957 xenograft model. Furthermore, the miR-101 level was inversely correlated with levels of @entity41183 , @entity3546 , and @entity4910 in western blotting assay and immunohistochemical staining assay. CONCLUSIONS: These results indicate that miR-101 is a potent @entity5 repressor that directly represses @entity41183 expression. Thus, detection and targeting of miR-101 may represent a novel diagnostic and therapeutic strategy for @entity957 @entity1 .

MicroRNA-101 is a potential prognostic indicator of @entity957 and modulates XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'tumours', 'tumour'] @entity19 :: ('10090', 'Species') :: ['Nude mice'] @entity957 :: ('MESH:D002294', 'Disease') :: ['LSCC', 'laryngeal squamous cell carcinoma'] @entity41183 :: ('1024', 'Gene') :: ['CDK8', 'Cyclin-dependent kinase 8'] @entity189 :: ('MESH:D002277', 'Disease') :: ['laryngeal carcinoma'] @entity4910 :: ('595', 'Gene') :: ['cyclin D1'] @entity3546 :: ('1499', 'Gene') :: ['b-catenin'] @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancers'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']
@entity41183 :: (1024,Gene) :: ['CDK8']
